You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Pan Pharmaceuticals on the way to recovery
Australia's medicines watchdog, the Therapeutic Goods Administration (TGA) today confirmed that its recent audit of the Pan Pharmaceuticals plant in Sydney found a satisfactory level of compliance with Good Manufacturing Practice requirements for the production of soft gel capsule products.
The company, which is in being administered by a liquidator/administrator, has indicated it will now apply formally for a licence reinstatement with conditions to restrict manufacture to low risk soft gel capsules such as herbals, vitamins and minerals.
Pending the company meeting the appropriate fit and proper person test, the TGA may be in a position to lift the licence suspension over the next week.
Media contact: Kay McNiece, Media Adviser, 0412 132 585